Loading…
Catalyst Pharmaceuticals, Inc. is projected to rise to $40.57 by 2027, a +29% move from its current price of $31.47. CPRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $31.21 | $31.49 | $31.77 | +0.07% |
| Jul 13 | $31.12 | $31.51 | $31.91 | +0.14% |
| Jul 14 | $31.05 | $31.54 | $32.03 | +0.21% |
| Jul 15 | $31.00 | $31.56 | $32.12 | +0.28% |
| Jul 16 | $30.96 | $31.58 | $32.21 | +0.35% |
| Jul 17 | $30.92 | $31.60 | $32.30 | +0.42% |
| Jul 18 | $30.89 | $31.62 | $32.38 | +0.49% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $30.89 | $31.62 | $32.38 | +0.49% |
| Week 2 | $30.74 | $31.78 | $32.85 | +0.98% |
| Week 3 | $30.66 | $31.93 | $33.26 | +1.47% |
| Week 4 | $30.61 | $32.09 | $33.63 | +1.97% |
| Week 5 | $30.59 | $32.25 | $33.99 | +2.46% |
| Week 6 | $30.59 | $32.40 | $34.33 | +2.97% |
| Week 7 | $30.60 | $32.56 | $34.65 | +3.47% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Catalyst Pharmaceuticals, Inc. (CPRX) is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic AMPA glutamate receptor, that is used to treat focal onset seizures as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of Duchenne muscular dystrophy."
The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
CPRX trades as a healthcare stock with a current price of $31.38 and a market cap of $3.84B. It is ranked 1568 by market capitalization. The near-term outlook shows a neutral stance for 2026, with an average price of $31.38 and an ROI of 0%.
Longer-term forecasts point to a bullish trajectory, with year-by-year upside through 2035 and beyond. By 2030 the average is projected to $74.75, and by 2050 the average is projected to $528.27, accompanied by sizable ROIs (e.g., 138.2% in 2030 and 1583.5% in 2050). These figures imply meaningful upside over the coming years, though they are estimates and not guaranteed.
A major floor 29.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.8% away) — a key level to hold.
Price is pressing into resistance (0.1% away) — a breakout level to watch.
A major ceiling 0.6% above — clearing it would confirm fresh momentum.
Key CPRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CPRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $31.48 | Sell | $31.47 | Sell |
| MA 10 | $31.47 | Buy | $31.46 | Buy |
| MA 20 | $31.43 | Buy | $31.38 | Buy |
| MA 50 | $31.08 | Buy | $30.46 | Buy |
| MA 100 | $27.91 | Buy | $28.66 | Buy |
| MA 200 | $25.23 | Buy | $26.42 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 69.10 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 69.88 | Neutral |
| Williams %R (14) | -25.00 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | 0.22 | Buy |
| Bollinger %B (20,2) | 0.73 | Neutral |
| Stochastic %K (14) | 75.00 | Neutral |
| TRIX (15) | 0.10 | Buy |
| Awesome (5,34) | 0.11 | Buy |
| Ultimate (7,14,28) | 68.82 | Neutral |
| Momentum (10) | 0.05 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 31.48 | Sell |
| ADX (14) | 42.11 | Buy |
| ATR (14) | 0.05 | Info |
30-day technical picture shows bullish momentum. RSI14 is 70, and the stock trades with a 50-day simple moving average of $29.70 and a 200-day simple moving average of $24.43. Short-term support is at $31.14 and resistance at $31.40. The 30-day range runs from $29.43 to $33.46, and annualized volatility stands around 20%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $22.33 | $31.47 | $42.08 | 0% | Neutral | |
| $33.23 | $40.57 | $51.79 | +29% | Bullish | |
| $37.26 | $46.34 | $60.76 | +47% | Bullish | |
| $47.64 | $60.18 | $80.59 | +91% | Bullish | |
| $59.47 | $76.14 | $103.79 | +142% | Bullish | |
| $65.44 | $84.81 | $117.43 | +169% | Bullish | |
| $76.94 | $100.83 | $141.60 | +220% | Bullish | |
| $83.25 | $110.25 | $156.83 | +250% | Bullish | |
| $86.72 | $115.99 | $166.98 | +269% | Bullish | |
| $100.43 | $135.59 | $197.37 | +331% | Bullish | |
| $163.81 | $230.67 | $351.86 | +633% | Bullish | |
| $363.97 | $549.68 | $898.79 | +16.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $22.33 | $31.47 | $37.44 | +0.00% |
| August 2026 | $28.05 | $32.84 | $39.28 | +4.35% |
| September 2026 | $28.51 | $33.53 | $40.42 | +2.11% |
| October 2026 | $28.12 | $33.21 | $40.30 | -0.95% |
| November 2026 | $28.26 | $33.49 | $40.86 | +0.83% |
| December 2026 | $28.86 | $34.32 | $42.08 | +2.48% |
Click any year to see its month-by-month CPRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CPRX could reach as high as $42.08, with a base case around $31.47 and support toward $22.33 — roughly 0% from $31.47. Price action looks broadly range-bound.
Expect CPRX to range from $33.23 to $51.79 through 2027. The $40.57 average target implies a +29% move from current prices. That is up +29% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The CPRX price prediction for 2028 points to an average of $46.34 (low $37.26, high $60.76) — a potential gain of +47% on today's $31.47. Momentum favours further upside here.
In 2029, CPRX is projected to trade between $47.64 and $80.59, averaging $60.18 — a potential gain of +91% from today's $31.47. That is up +30% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Catalyst Pharmaceuticals, Inc.'s 2030 outlook centres on $76.14, within a $59.47 to $103.79 range. That is up +27% on the projected 2029 average. That marks a +142% change versus current levels. Momentum favours further upside here.
By 2031, CPRX could reach as high as $117.43, with a base case around $84.81 and support toward $65.44 — roughly +169% from $31.47. Buyers look set to stay in control over this stretch.
Expect CPRX to range from $76.94 to $141.60 through 2032. The $100.83 average target implies a +220% move from current prices. That is up +19% on the projected 2031 average. Momentum favours further upside here.
The CPRX price prediction for 2033 points to an average of $110.25 (low $83.25, high $156.83) — a potential gain of +250% on today's $31.47. Buyers look set to stay in control over this stretch.
In 2034, CPRX is projected to trade between $86.72 and $166.98, averaging $115.99 — a potential gain of +269% from today's $31.47. That is up +5% on the projected 2033 average. Momentum favours further upside here.
Catalyst Pharmaceuticals, Inc.'s 2035 outlook centres on $135.59, within a $100.43 to $197.37 range. That is up +17% on the projected 2034 average. That marks a +331% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, CPRX could reach as high as $351.86, with a base case around $230.67 and support toward $163.81 — roughly +633% from $31.47. Momentum favours further upside here.
Expect CPRX to range from $363.97 to $898.79 through 2050. The $549.68 average target implies a +16.5x move from current prices. That is up +138% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CPRX today (≈ 31.776295 CPRX) could be worth
$17,466.95
+$16,466.95 (+1647%) by 2050 · US Dollar
Based on the average projected CPRX price of $549.68 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CPRXwould be worth at today's price.
$1,000 invested in CPRX on Jul 10, 2025 (≈ 45.76659 CPRX) would be worth
$1,440.27
+$440.27 (+44.0%) today · 1.44× · US Dollar
Based on a CPRX entry price of $21.85 vs. today's $31.47.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $31.45 | $1,000.64 | +0.1% |
| 1 month ago | $31.34 | $1,004.15 | +0.4% |
| 3 months ago | $24.94 | $1,261.83 | +26.2% |
| 6 months ago | $23.22 | $1,355.3 | +35.5% |
| 1 year ago | $21.85 | $1,440.27 | +44.0% |
| All time (5.0y) ago | $5.61 | $5,609.63 | +461.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CPRX forecast.
Our base-case forecast reaches $63.00 around 2030.
Implied market cap at $63.00: $7.71B
The multi-year forecast paints a rising trajectory with solid bullish sentiment from 2027 onward. The average price climbs from $40.05 in 2027 to $74.75 in 2030 (with a 138.2% ROI) and continues higher to $85.15 (2031), $99.34 (2032), and $107.86 (2033) before accelerating to $228.68 by 2040 (628.7% ROI) and $528.27 by 2050 (1583.5% ROI). The forecast sequence shows persistent upside, but these are estimates and not guarantees.
Investors should consider the potential for volatility and downside risk alongside the projected gains.
Tap a question to reveal the answer.
2030 forecast: avg $74.75, min $58.35, max $101.98; ROI 138.2%; sentiment bullish.
Forecasts show bullish sentiment from 2027 onward with rising averages and ROIs, including 2027 avg $40.05 (ROI 27.6%), 2030 avg $74.75 (ROI 138.2%), and 2050 avg $528.27 (ROI 1583.5%). These are estimates, not guarantees.
Yes. The 2030 maximum forecast is $101.98, which exceeds $100.
Current price is $31.38 and market cap is $3.84B.
RSI14 is 70. The 50-day SMA is $29.70 and the 200-day SMA is $24.43. Support is at $31.14 and resistance at $31.40. The 30-day range is $29.43 to $33.46, with annualized volatility of 20%.
Catalyst Pharmaceuticals, Inc. Community Discussion
0Share your Catalyst Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.